JP/EN
JP/EN

Transforming Health Care,
Transforming Society,
Transforming the World.

DIAMOND MEDINO CAPITAL

At DMC we believe that by understanding the real needs on the ground in the medical field, promoting collaboration between medicine and engineering, and making appropriate targeted investments we can make the world a better and happier place.

We discover the unpolished gemstones that are the latent talents of medical
researchers, and polish them into glittering diamonds.

CONCEPT

We boast connoisseur teams of Japanese experts who are ready to bring advanced technology to markets worldwide.

Game changer, DMC.

We will create the very first ecosystem in countries around the world from Japan, where the technologies focused on specially controlled medical devices and pharmaceuticals, as a result of successful healthcare startups, are quickly returned to society through timely investment and cross-sector partnership.

STRENGTH 1

Professors and specialist doctors familiar with the medical field on the ground and expert in medicine and engineering serve as connoisseurs identifying client needs, engage in technological development and work with our clients until they succeed.

STRENGTH 2

Our team of engineers, armed with broad perspectives and capable of responding to cutting-edge medical needs, will team up with outstanding/perception university professors and medical specialists for peerless technological development.

STRENGTH 3

Our team of leading Japanese financial specialists with rich investment experience can accurately identify technologies, markets and personnel at the initial seed stage, and work closely with promising researchers. We will support your start-up from inception through to your exit strategy.

STRENGTH 4

Our certified pharmaceutical specialists, who are familiar with the internal affairs of regulatory authorities in Japan and the United States, can provide hands-on support to obtain administrative approvals at every stage.

FUND

DMC 1st Fund
Investment Limited Partnership

TermTen years since Nov. 2022
Total size of fundJPY2.7bn
TargetInvesting in the life science field (medical devices, drug discovery)
Advisory bodyAdvisory board installed
Limited PartnersTANAKA Kikinzoku Kogyo K.K., Sumitomo Mitsui Trust Bank, Limited, Nobuyoshi Ehara et al.
Legal advisorTMI Associates
Statutory auditorIDEA Audit Firm

TEAM

Chief Executive Officer / General Partner
TERUMITSU HASEBE
  • Professor and Chairman, Department of Radiology, Tokai University Hachioji Hospital, Tokai University School of Medicine
  • Visiting Professor, Clinical and Translational Research Center, Keio University Hospital
  • Visiting Professor, Massachusetts Institute of Technology/Harvard-MIT Health Sciences and Technology (HST)
  • M.D./Ph.D. in Radiological Science/Ph.D. in Mechanical Engineering
Established the medical-engineering collaboration team "Hasebe Research Group" at Keio University's Faculty of Science and Technology. Since receiving his doctorate in engineering he has led the development of numerous medical devices in collaboration with medical device manufacturers while continuing to work as a practicing medical doctor.
His Tron FX cerebral thrombus remover marketed by Biomedical Solutions Inc. is known for saving many patient lives. He was responsible for the entire project, from preclinical studies through to licensing applications.
He is currently leading a project to develop the world’s first stent delivery system for below the knee peripheral vessels.
Chief Financial Officer/ General Partner
TAKAHIRO NAMEKATA
Joined Goldman Sachs as a new graduate in 1994 and belonged to the Fixed Income department as a trader for 12 years, in charge of derivatives, swaps, options and Japanese Gov’t Bond.
After that, he worked for one of the largest banks in Europe for 10 years, where he has overseen trading division in Tokyo and was responsible for the G10 linear products in Asia pacific zone as a managing director. He has served as deputy CEO in Tokyo.
He holds BS in Physics in Keio university, and MS in Material Science from graduate school of Keio univ.
Managing Director/ General Partner
NAOHIRO NISHIDA
Joined the Industrial Bank of Japan (today's Mizuho Bank) as a new graduate. After joining Goldman Sachs as a fixed income trader, he has over 11 years at Deutsche Bank Group and HSBC as Managing Director with extensive investment banking/global markets experience. In 2016, he founded Arco Partners Inc. to invest in and support a number of Japanese ventures.
He holds a bachelor's degree in economics from Keio University and graduated from Oxford University (MSc. in Development Economics) and LSE (MSc. In International Political Economy).
Managing Director
HIDEYUKI SAYA
  • Director, Oncology Innovation Center, Fujita Health University.
  • Professor Emeritus, Keio University
  • M.D./Ph.D. in Medicine
Graduated from Kobe University School of Medicine in 1981. After working as a postdoctoral fellow at UCSF, became an assistant professor (neuro-oncology) at MD Anderson Cancer Center in 1988. He conducted cancer research as a professor at the Kumamoto University School of Medicine (Department of Tumor Genetics and Biology) and Keio University School of Medicine until 2022, when he assumed his current position. 2021-2023 President, Japanese Cancer Association.
Managing Director
TETSUYA ISHIMARU
Led the anti-thrombogenic material study as an initial member of the “Hasebe Research Group” since 2005.
From 2008 worked for the world’s largest rail operator for 15 years as an engineer responsible for operation quality management of operation control, development/operation of core systems for rail operation planning with a focus on supplier management and project management, and decision process for systemizing investment and labor-saving. Was responsible for the rail franchise business in the UK and labor management for the domestic field operations unit.
Tetsuya holds an MS in Material Science from the Graduate School of Keio University.
Advisor
NOBUYOSHI EHARA
  • Founder of Unison Capital, Inc.
Graduated from the Massachusetts University of Technology Department of Architecture in 1975. In 1978 completed his MA at the University of Chicago Economics Department. After serving with Morgan Guaranty Trust Company, joined Goldman Sachs in 1980. He was the first Japanese partner to serve at Goldman Sachs’ U.S. headquarters.
In 1999 he founded Unison Capital, Inc. in Japan, serving as representative director. He is known as the “father” of private equity funds in Japan, and has vast experience in investing.